Abstract Thyroid hormone is important for skull bone growth, which primarily occurs at the cranial sutures and synchondroses. Thyroid hormones regulate metabolism and act in all stages of cartilage and bone development and maintenance by interacting with growth hormone and regulating insulin-like growth factor. Aberrant thyroid hormone levels and exposure during development are exogenous factors that may exacerbate susceptibility to craniofacial abnormalities potentially through changes in growth at the synchondroses of the cranial base. To elucidate the direct effect of in utero therapeutic thyroxine exposure on the synchondroses in developing mice, we provided scaled doses of the thyroid replacement drug, levothyroxine, in drinking water to pregnant C57BL6 wildtype dams. The skulls of resulting pups were subjected to micro-computed tomography analysis revealing less bone volume relative to tissue volume in the synchondroses of mouse pups exposed in utero to levothyroxine. Histological assessment of the cranial base area indicated more active synchondroses as measured by metabolic factors including Igf1. The cranial base of the pups exposed to high levels of levothyroxine also contained more collagen fiber matrix and an increase in markers of bone formation. Such changes due to exposure to exogenous thyroid hormone may drive overall morphological changes. Thus, excess thyroid hormone exposure to the fetus during pregnancy may lead to altered craniofacial growth and increased risk of anomalies in offspring.
Introduction
Thyroid hormone has been shown to be important for skull bone development and growth [1] . Its contribution has been noted at the cranial sutures [2] [3] [4] as well as the synchondroses [5] . Thyroid hormones are responsible for regulation of metabolism and are important for growth and development of the skeleton by acting during bone development and maintenance. Proper bone mineral densities are partially maintained by thyroid hormones interacting with factors such as growth hormone and aiding in the regulation of insulin-like growth factor (Igf) [6, 7] . These interactions effect linear bone growth by targeting the hypertrophic zone of cartilaginous growth plates [8] [9] [10] [11] . These same processes are important for the craniofacial skeleton, as the synchondroses of the cranial base, like the growth plate in long bones, contribute to elongation by proliferation and hypertrophy of chondrocytes. Unlike long bone growth plates, the synchondroses produce growth in opposing directions [12] .
As thyroid hormones have particularly potent effects on cartilage including the growth plates, it stands to reason that the cranial base synchondroses may be similarly targeted [13] . However, little work has been conducted to address this. Aberrant expression and circulation of thyroid hormones, including exposures via maternal thyroid replacement drug, have been linked to craniofacial growth disorders [14] [15] [16] . Further, the cranial base contributes to calvarial growth by proper development and maintenance of the coronal ring, which includes the coronal suture, frontosphenoidal suture, and presphenoethmoidal synchondrosis in humans [17] [18] [19] . In addition, the dural tracts which underlie the calvarial growth sites, including the spheno-occipital synchondrosis of the cranial base, allow for the interpretation that cranial base growth may affect overall calvarial expansion [20] . When cranial base growth is altered, aberrant craniofacial growth results [21] [22] [23] .
There are many exogenous factors that affect craniofacial growth [14, [24] [25] [26] [27] [28] . In the current study, we aim to elucidate the effect of in utero levothyroxine exposure on the cranial base and by extension craniofacial growth in mice. We hypothesize exposure to levothyroxine in utero will affect the cartilaginous portions of the cranial base in a dose-dependent manner involving specific changes in cranial base morphology, target protein expression, and cartilage cell metabolism.
Materials and Methods

In Vivo Exposure
Adult wild-type C57BL6 males and females were utilized to produce in utero levothyroxine exposed litters. Animals were bred and separated at *E13 of pregnancy. At this time, doses of levothyroxine (Synthroid) scaled for use in mice (control = no treatment; low dose *167 ng/day; high dose *667 ng/day) were added to the drinking water provided to pregnant dams [29] [30] [31] [32] [33] [34] [35] [36] . Treatments were timed for a critical period of craniofacial development, assigned randomly with the intention of producing 12 pups per group, and continued until birth of litters (*E20) when all animals were provided un-supplemented water [35] . Mouse pups were grown to postnatal day (P) 15, P20, or P25 when they were sacrificed and whole skulls were fixed with 4% paraformaldehyde for 48 h, then switched to 70% Ethanol for micro-computed tomography (lCT), and then further processed for histology. These Animal Use Protocols were approved by Georgia Regents University Institutional Animal Care and Use Committee (2011-0365), and the Medical University of South Carolina Institutional Animal Care and Use Committee (AR#3341). All breeding procedures were carried out in an Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility where all husbandry and related services are provided by the Division of Laboratory Animal Resources [37] .
Micro-Computed Tomography Analysis
lCT images were obtained on all collected skulls with a SkyScan 1174 (Kontich, Belgium) at a 19.17 lm voxel resolution (Table 1) . Skulls were stabilized using a custom cradle, and reconstructed with NRecon v1.6.4.8 (BrukermicroCT, Kontich, Belgium) as previously described [38] . Threshold settings were set to capture bone volume within the skull. Cranial base length was measured from basion to foramen cecum, and anterior and posterior base lengths were determined from spheno-occipital synchondrosis (SOS) to foramen cecum and basion to SOS, respectively. Measurements of the lengths, widths, and heights of the cartilaginous regions between ossified centers, SOS, and inter-sphenoidal synchondrosis (ISS) at the midline of the cartilaginous segment were recorded. A standardized region of interest that included cartilaginous synchondrosis and abutting bone was used to assess the Bone Volume compared to Tissue volume (BV/TV) (Fig. 1a) . Measures were compared at each time-point by split-plot KruskalWallis by postnatal time-point effects by dose; p B 0.05 was considered significant for post hoc Bonferroni analyses. All statistical analyses were completed using SPSS 23.0 (IBM, Armonk, NY, USA).
Histological Investigation
After lCT scanning, representative samples (n = 3) from each group (control, low, high) for each time-point (P15, P20, P25) were decalcified in 0.25 M EDTA at pH7.4 for 10 days. Samples were then washed, dehydrated in graded ethanol (70-100%), cleared in xylene, and embedded in paraffin. Histology was performed using 8 lm sections. Harris' hematoxylin (VWR, Radnor, PA, 10143-606) and Eosin (VWR, 95057-848) staining proceeded by standard protocol. As the SOS is the last synchondrosis of the cranial base to fuse in humans, it is assumed that it has a greater impact on craniofacial development, and thus we have focused on this region [12] . Three sections at least 30 lm apart were used for histomorphometric analysis. Stained sections were photographed using a Motic Inverted Microscope with attached camera (Motic, British Columbia, Canada). Standardized variables including total area including adjacent trabeculae, synchondrosis length and height, as well as the length of the isolated resting, proliferative, and hypertrophic zones were measured using Image J Software (National Institutes of Health) [31] .
Measures were compared for effects by dose, and p B 0.05 was considered significant.
For immunohistochemistry, representative samples (n = 3) from each group at P20 were subjected to antigen retrieval (10 mM Sodium Citrate Buffer). P20 was identified as being where the most differences between control and exposure groups were identified, and thus this timepoint was used for the remainder of the investigation. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide and then washed sections were blocked in 1% goat serum with 1% bovine serum albumin. Sections were incubated with the following primary antibodies for 1 h at room temperature or refrigerated overnight: Htra1 (AbCam Cambridge, MA, ab38611, 1:50), Igf1 (ab9572, 1:50), PCNA (ab18197, 1:3000), Alp (ab108337, 1:250), Active Caspase 3 (ab2302, 1:75), Type II collagen (ab34712, 1:600), Type X collagen (ab49945, 1:25), Aggrecan (ab36861, 1:200). Sections were washed and incubated with HRP-conjugated secondary antibody for 1 h (ab6721). Diaminobenzidine (DAB) (Vector Laboratories, Bulingame, CA) chromagen was used to identify immunoreactive structures. Whole synchondroses including abutting trabecular bone, as well as individual zones were digitally isolated for direct comparison between control and levothyroxine (low and high) exposed individuals. At least 3 sections 30 lm apart per individual per treatment for each target were analyzed using Image J Software and the IHC Profiler Open Source Plugin for automated scoring of percent positivity [39] . Measures were compared for effects by dose; p B 0.05 was considered significant.
To assess the maturity of the cellular matrix in the cartilaginous synchondrosis, picrosirius red staining was performed per standard protocol. Stained sections were photographed under polarized light using a Motic Inverted Microscope with attached camera. Contribution of green (immature), yellow (intermediate), and red (mature) fibers was assessed using Visopharm software (Visopharm, Hoerscholm Denmark).
Tissue-Based Quantitative Polymerase Chain Reaction
A set of randomly selected P20 skulls (n = 3 control, n = 3 high dose) were not fixed, but were used for RNA isolation from cranial base tissue. The cranial base including the cartilaginous regions of the SOS, and ISS and the intervening bone, was excised. The extirpated tissue was homogenized in a liquid nitrogen-cooled mortar and digested in TRIZOL (ThermoFisher). RNA was isolated using the Qiagen RNEasy mini kit (Qiagen, Valenica, CA, USA). Quantity and quality of RNA was assessed using a Synergy H1 Microplate reader and a Take3 Microvolume Plate (BioTek, Winooski, VT, USA). cDNA synthesis was performed using Superscript II Reverse Transcriptase and random hexamer primer (ThermoFisher) and then subjected to quantitative PCR using Applied Biosystems TaqMan Quantitative data were compared for gene expression change by DDCT. We used statistical analyses for qrt-PCR data as previously published to determine differences for gene expression after levothyroxine exposure [40] . Differences were considered significant if p B 0.05.
Western Blots on Cranial Base Tissue
A parallel set of randomly selected P20 skulls (n = 3 control, n = 3 high dose) were not fixed, but placed in ice cold PBS. Subsequently, the cranial base was identified and isolated as above. The tissue was then homogenized as above and protein was extracted with cold RIPA buffer (ThermoFisher). Total protein was quantified using a Bradford assay (ThermoFisher). Whole tissue protein extracts were separated by 10% SDS-PAGE. Equal amounts of protein per lane were loaded and transferred onto PVDF membrane (BioRad, Hercules, CA, USA). The blots were probed with the following antibodies diluted in Tris-buffered saline, 0.1% Tween 20 with 5% (wt/vol) bovine serum albumin: Htra1 (AbCam, ab38611, 1:1000), 
Results
In Utero Levothyroxine Exposure Alters the Murine Synchondrosis
Representative lCT reconstructions of isolated cranial bases from P15, P20, and P25 mice exposed to control, low, and high dose levothyroxine in utero are included in Fig. 1 . There was approximately equal representation of sex among 226 animals (Male = 39.2%; Female = 34.3%; Undetermined = 26.5%) ( Table 1) . Animal weight did not differ by sex, but was greater in high dose exposed at P15 and P20 but less at P25 (p \ 0.05) indicating long-term effects of exposure. Assessment of cranial base length indicates an increase in overall length in high dose exposed individuals as compared to control and low dose exposed at P20. That length is maintained to P25, while low dose exposed and control individuals increase in length. This relationship remained in both the anterior and posterior portions of the cranial base. Results suggest increased bone volume in the SOS with high dose exposure compared to control at P15 (p = 0.031), and a decreased bone volume in the ISS for both low and high doses compared to control (p \ 0.001, p = 0.017, respectively) and SOS for high dose compared to control (p = 0.025) at P20. This imbalance resolved by P25 (Fig. 1) . Figure 2 demonstrates representative H&E staining of sections of the SOS from P20 mice unexposed (control) or exposed to low or high dose levothyroxine (Fig. 2a-f) . Histomorphometric analysis was conducted on 3 individuals from each group (control, low, high) at P15, P20, and P25. The area of the SOS including the abutting trabeculae is less in the low dose exposure as compared to high dose at P15 and as compared to both control and high dose exposures at P20 (p \ 0.001). These differences were resolved by P25 (Fig. 2g) . Similarly, the length of the SOS is less in low dose treatment at P20 compared to control and high dose, and P25 compared to high dose (p \ 0.001) (Fig. 2h) . Changes to the height of the SOS were seen early with the low dose being shorter than control and high dose at P15 (p \ 0.001). At P20, high dose demonstrated greater height as compared to control (p \ 0.05) (Fig. 2i) . Investigation of the lengths of the specific zones of the SOS revealed longer central resting zones in low dose exposed individuals compared to control and high dose at P20 (p \ 0.001) (Fig. 2j) . For the proliferative zone, control (no exposure) was longer than both doses (p \ 0.05) at P20. At both P20 and P25, high dose exposed proliferative zone was longer than low dose (p \ 0.03) (Fig. 2k) . The hypertrophic zone abutting the trabeculae was longer in the high dose exposed at all time-points when compared to low dose (p \ 0.002). The control group was greater than both levothyroxine doses at P20 (p \ 0.001) (Fig. 2l) .
Histological Assessment of Cellular Activity in In Utero Levothyroxine Exposed Spheno-Occipital Synchondroses
Figure 3a-c demonstrates representative images of immunohistochemistry on sections of SOS from P20 mice either unexposed or exposed to levothyroxine. Zonespecific quantification of serine protease Htra1 staining indicates a decreased level of activity in the resting zone (p = 0.006) of the exposed synchondroses (both doses), and in the proliferative and hypertrophic zones of low dose exposed individuals as compared to control (p = 0.005) (Fig. 3a-d) . Staining for Igf1 which is partially regulated by Htra1 (Fig. 3e-h ) demonstrated a significant increase in staining with high dose exposure (p = 0.008) when the cartilaginous region was combined with the adjacent trabecular bone. Additionally, within the isolated resting zone, low dose exposure demonstrated significantly less Igf1 staining compared to high dose exposure (p = 0.009). Assessment of gene activity indicated a decrease in Igf1 expression with high-dose exposure (p \ 0.05) (Fig. 3i) . No significant differences in Htra1 or Igf1 protein levels were observed (Fig. 3j-k) .
b Fig. 1 Effects of in utero levothyroxine exposure on murine sphenooccipital and inter-spenoidal synchondrosis morphology. a-c. Endocranial (above) and sagittal (below) view of representative lCT reconstructions of P15 (a), P20 (b), and P25 (c) mouse skulls exposed to control (no exposure, left), low (*167 ng/day, middle), and high (*667 ng/day, right) dosages of levothyroxine. Surrounding structures have been digitally cropped and an example area of analysis has been boxed. SOS (arrow). ISS (arrowhead). Whole skull insets (a) indicate orientation. d lCT assessment of SOS micro-architecture suggests increased bone volume with high dose exposure compared to control at P15 and the opposite at P20. e-g Measure of cranial base length indicates an increase in high dose exposed individuals as compared to control and low dose at P20. At P25, low dose exposed is greater than high and control. This relationship is maintained in both the anterior and posterior cranial base. h lCT assessment of ISS micro-architecture suggests increased bone volume with both low and high dose exposures at P20 compared to control. All measurements presented as mean ± SEM. Different than control: *p = 0.05-0.011; **p = 0.01-0.001; ***p \ 0.001 Different between doses: #p = 0.05-0.011; ##p = 0.01-0.001; ###p \ 0.001 Fig. 2 Histomorphometric assessment of spheno-occipital synchondrosis morphology after in utero levothyroxine exposure. a-f Representative low (a, c, e) and high (b,d,f) maginification hematoxylin and eosin stained SOS from P20 mice exposed to control (a-b), low (c-d), and high (e-f) doses of levothyroxine. Synchondrosis plus adjacent trabeculae is outlined (a). Resting zone (RZ), proliferative zone (PZ), hypertrophic zone (HZ), and trabecula bone (TB) are noted. g Assessment of area of the SOS including adjacent trabeculae indicates decreased area for the low dose exposed at P15 (compared to high dose), and at P20 (compared to control and high dose). h Length of the SOS indicating narrowing with low dose exposure at P20 (compared to control and high dose) and P25 (compared to high dose). i Height of the SOS demonstrates decreased height with low dose exposure at P15 (compared to control and high dose), and increased height with high dose exposure at P20 (compared to control). j Resting zone length increased with low dose exposure at P20. k Proliferative zone length was greater in control at P20 (compared to low and high doses) and low dose was less than high dose exposed at both P20 and P25. l Length of the hypertrophic zone was greater in high dose exposed as compared to low dose at P15, P20, and P25; however, length of the control was greatest at P20. All measurements presented as mean ± SEM. * p = 0.05-0.011; ** p = 0.01-0.001; *** p \ 0.001 Figure 4 demonstrates representative images of PCNA staining. No statistically significant differences in staining intensity were found (Fig. 4a-d) . Increased Alp activity was observed in the high dose exposed synchondroses (p = 0.004) (Fig. 4e-h ). In addition to increased Alp activity in high dose exposed, a significant increase in Caspase 3 activity was found. The cartilaginous synchondrosis (p \ 0.001), the proliferative zone (p = 0.002), the hypertrophic zone (p \ 0.001), and the isolated adjacent trabeculae (p = 0.05) of levothyroxine exposed pups demonstrate increased activity compared to control. Further, the proliferative zone demonstrated increased caspase activity in the high dose as compared to low (Fig. 4i-l) . On the level of gene expression however, only Alp expression is significantly decreased with exposure to levothyroxine (p \ 0.05) (Fig. 4m) . Assessment of protein indicates no significant differences (Fig. 4n-o) . Figure 5 demonstrates representative staining of the extracellular matrix in and around the SOS of P20 mouse pups unexposed or exposed to high or low levels of levothyroxine. Low magnification picrosirius red staining (Fig. 5a-c) demonstrates greater density of collagen fibers in the trabeculae of high dose exposed individuals. Polarization and higher magnification of the same samples ( Fig. 5d-f ) reveals a greater density of mature orange/red and less mature blue/green fibers in the exposed samples as compared to control samples. Quantification of the prevalence of those colors indicates significantly more green, yellow, and red fibers in the exposed samples (p \ 0.009) (Fig. 5g) . Type II collagen (Fig. 5h-k) is abundant in both groups. Zone specific quantification of staining intensity Fig. 3 Histological markers of cell metabolism in control and levothyroxine exposed spheno-occipital synchondroses. a-d Immunohistochemistry staining for serine protease Htra1 on cranial base SOS from P20 pups either unexposed (a) or exposed to low (b) or high (c) doses of levothyroxine. Increased staining in the control (a) was confirmed with quantification of percent staining (d). e-h Immunohistochemistry staining for insulin-like growth factor (Igf1) on cranial base SOS from P20 mouse pups either unexposed (e) or exposed to low (f) or high (g) doses of levothyroxine. Increased staining in the resting zone and trabeculae of the exposed sample was confirmed with quantification (h). i-k Gene expression for Htra1 and Igf1 in cranial base derived tissue reveals a decrease in Igf1 expression in high dose exposed tissue (i); however, western blot analysis indicated no change due to exposure (j-k). All measurements presented as mean ± SEM. indicates an increase in type II collagen in the hypertrophic zone of exposed cranial bases (p = 0.006). Type X collagen (Fig. 5l-o) is also identified in unexposed and levothyroxine exposed samples. No significant differences in staining intensity were identified. Likewise, Aggrecan (Fig. 5p-s) can be observed in both groups. More intense staining was found in the synchondrosis and adjacent trabeculae of the control specimen (p = 0.003). This decreased aggrecan staining in the exposed samples matched the gene expression assessment (p \ 0.05) (Fig. 5t) .
Histological Assessment of Cellular Matrix Formation of In Utero Levothyroxine Exposed Spheno-Occipital Synchondroses
Discussion
Here we sought to elucidate the effect of in utero levothyroxine exposure on the synchondroses of the mouse. In agreement with previous data revealing a brachycranic phenotype, and a shortened bone length, individuals exposed to high (*667 ng/day) dosages of levothyroxine presented with decreased cranial base length [41, 42] . Both low (*167 ng/day) and high dosages of levothyroxine correlate with decreased bone volume in the cranial base at P20. The cranial base has a primary role in Fig. 4 Histological markers of proliferation and bone formation in control and levothyroxine exposed spheno-occipital synchondroses. a-d Cranial base SOS from control unexposed (a), low (b), and high (c) dose levothyroxine exposed P20 mice stained for Proliferating Cell Nuclear Antigen (PCNA). Quantification of percent staining revealed no significant differences (d). e-h SOS from control unexposed (e) low (f), and high (g) dose levothyroxine exposed P20 mice stained for alkaline phosphatase (Alp) activity. Note increased staining in the exposed synchondrosis ? trabeculae (h). i-l SOS from control unexposed (i), low (j) and high (k) dose levothyroxine exposed P20 mice stained for apoptotic activity (active Caspase 3). Quantification of percent staining concurred with the qualitative assessment of more staining in the exposed samples (l). m-o. Gene expression for proliferation (Ki67), apoptosis (Caspase 3), and differentiation (Alp) indicated decreased expression of Alp with exposure (m); however, western blot analysis indicated no change due to exposure (n-o). All measurements presented as mean ± SEM. Histological markers of matrix composition in control and levothyroxine exposed spheno-occipital synchondroses. a-g SOS from control unexposed (a, d), low (b, e), and high (c, f) dose levothyroxine exposed P20 mice stained with picrosirius red. Unpolarized images (a-c) highlight greater density of collagen fibers emanating from hypertrophic zones of exposed synchondroses. Polarization (d-f), higher magnification (insets), and quantification (g) of the same samples reveal more collagen fibers of all types in exposed samples. h-k Immunohistochemistry staining for Type II collagen (h-k), Type X collagen (l-o), and aggrecan (p-s) on SOS from P20 pups unexposed (h, l, p), or exposed to low (i, m, q) or high (j, n, r) doses of levothyroxine. Quantification of percent staining confirmed Type II collagen is abundant throughout the synchondroses of exposed individuals (k), whereas type X collagen (o) and aggrecan (s) are less abundant. t Gene expression for Type II collagen (Col2a1), Type X collagen (ColX), and Aggrecan (Acan) in cranial base tissue reveals a decrease in Acan expression in exposed tissue. All measurements presented as mean ± SEM. Different than control: *p = 0.05-0.011; **p = 0.01-0.001; ***p \ 0.001. Different between doses: #p = 0.05-0.011; ##p = 0.01-0.001; ###p \ 0.001 driving postnatal growth and form, and both the intersphenoidal and spheno-occipital (ISS and SOS) synchondroses remain patent in wild-type mice up to P20 [43] . The decreased bone volume with exposure seen at P20 could indicate a delay in ablation of the cartilaginous regions of the cranial base. Fusion of the pre-and basi-sphenoid and basioccipital bones normally occurs via bony outgrowths extending from the ectocranial margins of the bones of the cranial base. Thus, some areas of the synchondrosis remain patent while others fuse [43] . Cranial dysmorphology may arise from abnormal cranial base, facial bone, or calvarial suture growth. Small but biologically significant changes in any of these regions may be difficult to observe radiographically, but can result in craniofacial abnormalities [18, 43, 44] . Further, changes in the growth trajectory of the cranial base may contribute to craniofacial growth disturbances [21] [22] [23] . Examination of cranial bases from P20 wild-type mice exposed and unexposed (control) indicate differences in cranial base composition as specified by changes in area, length, and height of the low dose exposed individuals as compared to both the control and the higher dose exposed synchondroses. The most dramatic effects of levothyroxine exposure on the morphology of the cranial base are observed at P20 indicating that levothyroxine exposure may interfere with expected synchondrosis fusion [43] . That the low dose exposure was observed to have a greater overall effect on synchondroses morphology may be indicative of a response that is specific to that dosage. Overall, it is interesting that most differences due to exposure were resolved by P25 perhaps indicating some compensatory growth.
Assessment of cellular activity within the SOS revealed an overall increase in Igf1 activity via immunohistochemistry. Similar results were not observed for gene expression or protein levels. These results may indicate specificity of the effect to the cartilaginous cranial base. Our immunohistochemical assessment allowed for localization of Igf1 activity to the cartilaginous cranial base, whereas the other assessments may include confounding factors from surrounding tissue. The correlation between increased thyroid hormone and Igf1 enhanced bone formation has been well established and here we observe increased Igf1 activity in the synchondroses of mice exposed to levothyroxine [2, 8] . Such Igf1 activity effects chondrocyte proliferation, while Htra1 activity is associated with chondrocyte differentiation. Binding of Htra1 with Igf1 provides a regulatory mechanism slowing the turnover of cartilage matrix for mineralized bone [13, 45] . The increase in Igf1 activity along with the decrease in Htra1 activity and the decrease in bone volume in synchondroses exposed to levothyroxine may be indicative of interference with the pace of craniofacial growth and development at the cranial base [1, 11, 45] . Further, differences in Igf1 and Htra1 activity between dosages may indicate multiple levels of interference. This interference is further validated by the increase in Alp and apoptotic activity observed in the synchondroses exposed to levothyroxine. The increases in Alp and Caspase 3 activity may indicate an acceleration of bone formation and cell turnover precipitating premature cell ablation in the synchondroses. Overall, the synchondroses from exposed individuals appear to be more active (increased differentiation and cell turnover) suggesting an interference with the tight regulation of cell cycling needed to maintain this important region. It is possible that the observed changes to cell metabolism, differentiation, and apoptosis are indicative of accelerated growth associated with thyrotoxicosis. Growth within the synchondroses may be accelerated, and then may resolve to early quiescence disrupting the expected progression of synchondrosis fusion [42] . The differences observed between dosages may indicate different pacing of cranial base fusion.
It is likely that the observed increase in Igf1 activity drives the maturation of the extracellular matrix in the synchondroses exposed to levothyroxine. However, it is also possible that such matrix maturation is a direct effect of the levothyroxine exposure. Thyroid hormone has been found to act directly on the hypertrophic zone of endochondral bone formation causing accelerated maturation of the chondrocytes resulting in changes to the extracellular matrix composition including those noted here [13] . The levothyroxine exposed groups presented with more collagen type II in the hypertrophic zone indicating matrix that is actively processing towards bone. An increase in the presence of type II collagen has been correlated with an increase in Igf1 activity specifically in proliferating cells (proliferative and hypertrophic zones) [8, 11] . Additionally, thyroid hormone promotes hypertrophic chondrocyte differentiation towards mature chondrocytes which produce collagen type X [9, 13] . Increases in Htra1 activity have been shown to enhance removal of cartilage matrix to allow for the formation of mineralized bone matrix [45] .
Here we see increases in Igf1 activity without an increase in Htra1 activity which may be responsible for the abundance of matrix observed in the exposed synchondroses.
The synchondroses from mice exposed to levothyroxine are likely displaying two separate effects driving change in cranial base composition which ultimately may drive the observed alterations to craniofacial morphology [41] . Firstly, we observe increased Igf1 signaling which induces a change in cellular activity in the growth center [2, 8] . Secondly, exposure to levothyroxine appears to cause an acceleration of bone growth by affecting the maturation of hypertrophic chondrocytes [6, 10, 13, 15] . Together these factors are likely responsible for the increased metabolic activity found in the synchondrosis of mice exposed to levothyroxine. Disruption via genetic or epigenetic factors to the tightly regulated developmental processes in this anatomical region can have significant and lasting effects on craniofacial development [44] . These data allow for the interpretation that high levels of thyroid hormone during pregnancy may lead to an increased risk of craniofacial abnormalities in offspring.
